569 related articles for article (PubMed ID: 15485464)
1. Evaluation of primary haemostasis in people with neurofibromatosis type 1.
Favaloro EJ; Zafer M; Nair SC; Hertzberg M; North K
Clin Lab Haematol; 2004 Oct; 26(5):341-5. PubMed ID: 15485464
[TBL] [Abstract][Full Text] [Related]
2. von Willebrand disease in a pediatric-based population--comparison of type 1 diagnostic criteria and use of the PFA-100 and a von Willebrand factor/collagen-binding assay.
Dean JA; Blanchette VS; Carcao MD; Stain AM; Sparling CR; Siekmann J; Turecek PL; Lillicrap D; Rand ML
Thromb Haemost; 2000 Sep; 84(3):401-9. PubMed ID: 11019962
[TBL] [Abstract][Full Text] [Related]
3. PFA-100 monitoring of von Willebrand factor (VWF) responses to desmopressin (DDAVP) and factor VIII/VWF concentrate substitution in von Willebrand disease type 1 and 2.
van Vliet HH; Kappers-Klunne MC; Leebeek FW; Michiels JJ
Thromb Haemost; 2008 Sep; 100(3):462-8. PubMed ID: 18766263
[TBL] [Abstract][Full Text] [Related]
4. Platelet von Willebrand factor determination does not improve the diagnosis of patients with suspected Type 1 von Willebrand disease.
Shihong I; Morris D; Konkle BA
Haemophilia; 2009 Jan; 15(1):131-4. PubMed ID: 18976254
[TBL] [Abstract][Full Text] [Related]
5. Perioperative monitoring of primary and secondary hemostasis in coronary artery bypass grafting.
Hertfelder HJ; Bös M; Weber D; Winkler K; Hanfland P; Preusse CJ
Semin Thromb Hemost; 2005; 31(4):426-40. PubMed ID: 16149021
[TBL] [Abstract][Full Text] [Related]
6. PFA-100 closure times in preoperative screening in 500 pediatric patients.
Roschitz B; Thaller S; Koestenberger M; Wirnsberger A; Leschnik B; Fritsch P; Muntean W
Thromb Haemost; 2007 Jul; 98(1):243-7. PubMed ID: 17598019
[TBL] [Abstract][Full Text] [Related]
7. Comparison of the O'Brien filter test and the PFA-100 platelet analyzer in the laboratory diagnosis of von Willebrand's disease.
Schlammadinger A; Kerenyi A; Muszbek L; Boda Z
Thromb Haemost; 2000 Jul; 84(1):88-92. PubMed ID: 10928476
[TBL] [Abstract][Full Text] [Related]
8. Comparison of the pharmacokinetics of two von Willebrand factor concentrates [Biostate and AHF (High Purity)] in people with von Willebrand disorder. A randomised cross-over, multi-centre study.
Favaloro EJ; Lloyd J; Rowell J; Baker R; Rickard K; Kershaw G; Street A; Scarff K; Barrese G; Maher D; McLachlan AJ
Thromb Haemost; 2007 Jun; 97(6):922-30. PubMed ID: 17549293
[TBL] [Abstract][Full Text] [Related]
9. Assessment of bleeding disorders in Sheehan's syndrome: are bleeding disorders the underlying cause of Sheehan's syndrome?
Gokalp D; Tuzcu A; Bahceci M; Ayyildiz O; Erdemoglu M; Alpagat G
Platelets; 2011; 22(2):92-7. PubMed ID: 21133650
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of desmopressin effects on haemostasis in children with congenital bleeding disorders.
Hanebutt FL; Rolf N; Loesel A; Kuhlisch E; Siegert G; Knoefler R
Haemophilia; 2008 May; 14(3):524-30. PubMed ID: 18284449
[TBL] [Abstract][Full Text] [Related]
11. Blood coagulation, fibrinolytic activity and lipid profile in subclinical thyroid disease: subclinical hyperthyroidism increases plasma factor X activity.
Erem C
Clin Endocrinol (Oxf); 2006 Mar; 64(3):323-9. PubMed ID: 16487444
[TBL] [Abstract][Full Text] [Related]
12. Laboratory monitoring of therapy in von Willebrand disease: efficacy of the PFA-100 and von Willebrand factor:collagen-binding activity as coupled strategies.
Favaloro EJ
Semin Thromb Hemost; 2006 Sep; 32(6):566-76. PubMed ID: 16977567
[TBL] [Abstract][Full Text] [Related]
13. Characterization of recessive severe type 1 and 3 von Willebrand Disease (VWD), asymptomatic heterozygous carriers versus bloodgroup O-related von Willebrand factor deficiency, and dominant type 1 VWD.
Michiels JJ; Berneman Z; Gadisseur A; van der Planken M; Schroyens W; van de Velde A; van Vliet H
Clin Appl Thromb Hemost; 2006 Jul; 12(3):277-95. PubMed ID: 16959681
[TBL] [Abstract][Full Text] [Related]
14. Utility of the platelet function analyser (PFA-100/200) for exclusion or detection of von Willebrand disease: A study 22 years in the making.
Favaloro EJ
Thromb Res; 2020 Apr; 188():17-24. PubMed ID: 32036157
[TBL] [Abstract][Full Text] [Related]
15. von Willebrand disease: a laboratory approach.
Trasi S; Ghosh K; Shetty S; Mohanty D
Natl Med J India; 2005; 18(2):78-84. PubMed ID: 15981443
[TBL] [Abstract][Full Text] [Related]
16. Characterization, classification, and treatment of von Willebrand diseases: a critical appraisal of the literature and personal experiences.
Michiels JJ; Gadisseur A; Budde U; Berneman Z; van der Planken M; Schroyens W; van de Velde A; van Vliet H
Semin Thromb Hemost; 2005 Nov; 31(5):577-601. PubMed ID: 16276467
[TBL] [Abstract][Full Text] [Related]
17. Variables influencing Platelet Function Analyzer-100 closure times in healthy individuals.
Haubelt H; Anders C; Vogt A; Hoerdt P; Seyfert UT; Hellstern P
Br J Haematol; 2005 Sep; 130(5):759-67. PubMed ID: 16115134
[TBL] [Abstract][Full Text] [Related]
18. Potential laboratory misdiagnosis of hemophilia and von Willebrand disorder owing to cold activation of blood samples for testing.
Favaloro EJ; Soltani S; McDonald J
Am J Clin Pathol; 2004 Nov; 122(5):686-92. PubMed ID: 15491964
[TBL] [Abstract][Full Text] [Related]
19. Laboratory diagnosis and monitoring of desmopressin treatment of von Willebrand's disease by flow cytometry.
Giannini S; Mezzasoma AM; Leone M; Gresele P
Haematologica; 2007 Dec; 92(12):1647-54. PubMed ID: 18055988
[TBL] [Abstract][Full Text] [Related]
20. Use of the PFA-100 in the assessment of primary, platelet-related hemostasis in a pediatric setting.
Rand ML; Carcao MD; Blanchette VS
Semin Thromb Hemost; 1998; 24(6):523-9. PubMed ID: 10066147
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
